304 related articles for article (PubMed ID: 10524938)
1. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.
Burchardt T; Burchardt M; Chen MW; Cao Y; de la Taille A; Shabsigh A; Hayek O; Dorai T; Buttyan R
J Urol; 1999 Nov; 162(5):1800-5. PubMed ID: 10524938
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
[TBL] [Abstract][Full Text] [Related]
3. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
4. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
5. A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells.
Yang X; Chen MW; Terry S; Vacherot F; Chopin DK; Bemis DL; Kitajewski J; Benson MC; Guo Y; Buttyan R
Cancer Res; 2005 Jun; 65(12):5263-71. PubMed ID: 15958572
[TBL] [Abstract][Full Text] [Related]
6. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
9. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L
Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
Yuan TC; Veeramani S; Lin MF
Endocr Relat Cancer; 2007 Sep; 14(3):531-47. PubMed ID: 17914087
[TBL] [Abstract][Full Text] [Related]
13. Prostate carcinoma response to cytotoxic therapy: in vivo resistance.
Teicher BA; Kakeji Y; Ara G; Herbst RS; Northey D
In Vivo; 1997; 11(6):453-61. PubMed ID: 9509295
[TBL] [Abstract][Full Text] [Related]
14. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
15. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
17. Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice.
DeMiguel F; Lee SO; Lou W; Xiao X; Pflug BR; Nelson JB; Gao AC
Prostate; 2002 Jul; 52(2):123-9. PubMed ID: 12111703
[TBL] [Abstract][Full Text] [Related]
18. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
[TBL] [Abstract][Full Text] [Related]
19. Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model.
McAlhany SJ; Ressler SJ; Larsen M; Tuxhorn JA; Yang F; Dang TD; Rowley DR
Cancer Res; 2003 Sep; 63(18):5859-65. PubMed ID: 14522910
[TBL] [Abstract][Full Text] [Related]
20. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
Siu SW; Lau KW; Tam PC; Shiu SY
Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]